Material Event Form 8 K

Item 8.01. Other Events.

Cingulate Inc. (the "Company") has raised a total of approximately $11.7 million in capital during August and September of 2024. Based on planned expenditures, this additional capital provides the Company the cash runway to fund clinical, manufacturing, and regulatory activities, as well as operating costs, through the second quarter of 2025. Filing of the NDA for potential FDA approval of CTx-1301 is targeted for mid-2025. As of September 30, 2024, the Company had cash and cash equivalents of approximately $10 million.